Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>In reviewing the latest results from Edwards Lifesciences, notable elements of growth and development paired with challenges shed light on the company's financial and operational trajectory during the second quarter of 2024.</li><li>With total company sales reaching $1.6 billion, this marked an 8% increase on a constant currency basis compared to the same period last year.</li><li>While Transcatheter Aortic Valve Replacement (TAVR) growth was not as robust as expected, increasing by 6% globally, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated impressive growth, with a 75% increase in sales.</li></ul>

In reviewing the latest results from Edwards Lifesciences, notable elements of growth and development paired with challenges shed light on the company's financial and operational trajectory during the second quarter of 2024.With total company sales reaching $1.6 billion, this marked an 8% increase on a constant currency basis compared to the same period last year.While Transcatheter Aortic Valve Replacement (TAVR) growth was not as robust as expected, increasing by 6% globally, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated impressive growth, with a 75% increase in sales.

Edwards Lifesciences Corporation: Strategic Acquisitions & Expansion into Heart Failure Management As A Key Growth Catalyst! - Major Drivers

<ul><li>Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts.</li><li>The company's total sales rose by 10% to $1.6 billion against the same period last year, leading Edwards to raise its 2024 sales guidance to the high end of 8% to 10%.</li><li>This highlights the company's successful strategic direction, underscored by its substantial investments across transcatheter platforms which are addressing patient needs associated with aortic, mitral, and tricuspid diseases.</li></ul>

Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts.The company's total sales rose by 10% to $1.6 billion against the same period last year, leading Edwards to raise its 2024 sales guidance to the high end of 8% to 10%.This highlights the company's successful strategic direction, underscored by its substantial investments across transcatheter platforms which are addressing patient needs associated with aortic, mitral, and tricuspid diseases.

Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives! - Major Drivers

<ul><li>Edwards Lifesciences, a medical technology company specializing in artificial heart valves and hemodynamic monitoring, recently reported the Fourth Quarter 2023 Earnings, where insights about the company's past performance and future prospects were shared.</li><li>The company's CEO, Bernard Zovighian, highlighted a strong financial performance in 2023, with a sales increment of 12% reaching up to $6 billion, building a strong presence across all four product groups.</li><li>Investments in research and development went beyond $1 billion, and it hit strategic milestones like the introduction of innovative technologies for sustainable growth.</li></ul>

Edwards Lifesciences, a medical technology company specializing in artificial heart valves and hemodynamic monitoring, recently reported the Fourth Quarter 2023 Earnings, where insights about the company's past performance and future prospects were shared.The company's CEO, Bernard Zovighian, highlighted a strong financial performance in 2023, with a sales increment of 12% reaching up to $6 billion, building a strong presence across all four product groups.Investments in research and development went beyond $1 billion, and it hit strategic milestones like the introduction of innovative technologies for sustainable growth.

Edwards Lifesciences Corporation: Will Its Investments in Field Expansion and Patient Activation Programs Pay Off? - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.</li>
<li>In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.</li>
<li>Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.</li>
</ul>



Asahi Intecc (7747 JP) is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.
In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.
Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.


2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

United States

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease. The Company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences supplies its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edwards Lifesciences (EW UN)

Edwards Lifesciences Corporation: Strategic Acquisitions & Expansion into Heart Failure Management As A Key Growth Catalyst! - Major Drivers

In reviewing the latest results from Edwards Lifesciences, notable elements of growth and development paired with challenges shed light on the...

Baptista Research

Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives! - Major Drivers

Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts. The company's total sales...

Baptista Research

Edwards Lifesciences Corporation: Will Its Investments in Field Expansion and Patient Activation Programs Pay Off? - Major Drivers

Edwards Lifesciences, a medical technology company specializing in artificial heart valves and hemodynamic monitoring, recently reported the...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Edwards Lifesciences Corporation: Strategic Acquisitions & Expansion into Heart Failure Management As A Key Growth Catalyst! - Major Drivers

In reviewing the latest results from Edwards Lifesciences, notable elements of growth and development paired with challenges shed light on the...

Baptista Research

Edwards Lifesciences Corporation: Increased Investment in Field Resources and Patient Access Initiatives! - Major Drivers

Edwards Lifesciences Corporation recorded robust first quarter 2024 results, demonstrating growth on numerous fronts. The company's total sales...

Baptista Research

Edwards Lifesciences Corporation: Will Its Investments in Field Expansion and Patient Activation Programs Pay Off? - Major Drivers

Edwards Lifesciences, a medical technology company specializing in artificial heart valves and hemodynamic monitoring, recently reported the...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...